Authors
Latest:
Which Treatment for Which Patient: Rectal Cancer Management After PROSPECT TrialDetermining treatment options for patients with locally advanced rectal cancer after the PROSPECT trial data readout adds an important level to the decision-making process.
Latest:
Circulating Tumor DNA as a Marker of Minimal Residual DiseaseBen Fangman, MD, and colleagues provide an overview of the use of circulating tumor DNA levels to detect minimal residual disease in colorectal cancer.
Latest:
Clinically Meaningful Outcome Measures: A Role for Geriatric AssessmentNora Kovar, MD, MPH; and Melissa L. Teply, MD, give their perspective on research from Quirin Zangl, MD, published in ONCOLOGY regarding geriatric assessment in patients with genitourinary carcinoma.
Latest:
Oncology Peer Review On-The-Go: Improving Testing Access and Guiding Treatment Options with TrialJectoryThe latest podcast episode of Oncology Peer Review On-The-Go features a conversation with Tzvia Bader and Karine Perreault on TrialJectory’s platform, which seeks to guide patients with cancer on their treatment journey.
Latest:
Expert Commentary On The Product Profile Of DostarlimabIn an interview with ONCOLOGY®, Megan May, PharmD, BCOP, offers a comprehensive review of real-world treatment considerations of dostarlimab as therapy for adult patients with recurrent or advanced solid tumors with deficient mismatch repair.
Latest:
Key Takeaways on the Treatment of Patients With Relapsed/Refractory MMThe expert panel closes the discussion with key takeaways on the relapsed/refractory multiple myeloma treatment landscape.
Latest:
Clinical Scenario: AE Management for Bispecific Therapy in R/R MMFollowing the review of a case of a patient with relapsed/refractory multiple myeloma, the panel provides expert perspectives on adverse event management practices.
Latest:
Key Takeaways from Health Care Systems on the Role of Bispecifics in MMThe panel closes their discussion by highlighting crucial takeaways about the use of bispecific antibodies in the treatment of multiple myeloma.
Latest:
Kidney Cancer Research Program May Play Pivotal Role in Advancing CareAn “avalanche of funding” has propelled the kidney cancer field forward, says Jason Muhitch, PhD.
Latest:
Rare Primary ALK-Positive Anaplastic Large Cell Lymphoma of the Central Nervous SystemAnaplastic large cell lymphoma is a rapidly growing and aggressive hematological malignancy. This case highlights the rarity of isolated intradural extramedullary manifestations in the pediatric population.
Latest:
Clinical Insights Surrounding CheckMate 9ER Updates and Use of Nivolumab Plus Cabozantinib in ccRCCToni Choueiri, MD, and Rohit Gosain, MD summarize the implications of the CheckMate 9ER 3-year follow-up data and highlight remaining questions and unmet needs in the RCC landscape.
Latest:
Managing CNS and Systemic Responses In R/R MM: Monitoring and Sequencing Strategies with Elranatamab and Cilta-CelPanelists discuss how, for a patient who has an aggressive disease, physicians will plan for monthly serum markers including serum protein electrophoresis (SPEP) and immunofixation electrophoresis (IFE); if they start seeing an increase in the disease, they plan an imaging for bone marrow biopsy and consider a diagnostics lumbar puncture.
Latest:
Updates in Surgical Management of the AxillaAxillary management of patients with breast cancer such as sentinel lymph node biopsy have evolved substantially over the past 30 years.
Latest:
Biagio Ricciuti, MD, Looks Toward Future Research in NSCLC Involving PD-L1 ExpressionBiagio Ricciuti, MD, spoke about future analyses and major takeaways of a study analyzing outcomes with frontline immunotherapy based on PD-L1 expression in patients with non–small cell lung cancer.
Latest:
Looking Ahead and Key Takeaways in EGFRm NSCLCPanelists discuss how overcoming resistance mechanisms in EGFR-mutated non–small cell lung cancer (NSCLC) remains a key unmet need, with future research focusing on targeting these mechanisms, exploring new drug combinations, and optimizing treatment sequences to improve patient outcomes.
Latest:
Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled TrialsThe aim of this meta-analysis is to analyze the efficacy of these drugs in the treatment of mCRPC in terms of progression-free survival (PFS) and overall survival (OS), using the results of completed trials.
Latest:
Management of Residual Disease After First-line Chemotherapy in a Patient With a Nonseminomatous Germ Cell TumorIn this edition of Clinical Quandaries, Regina Barragan-Carrillo, MD, and colleagues present a case of an 18-year-old man who has a 1-month history of nonpainful right testicular enlargement.
Latest:
Unmet Needs and Future Perspectives for CAR T-Cell Therapy in R/R MMThe panel concludes by offering key takeaways on the treatment of patients with relapsed/refractory multiple myeloma who receive CAR T-cell therapy.
Latest:
Lorlatinib Yields Distinguishing CNS Benefit in ALK-Positive NSCLCTreatment with lorlatinib might be effective regardless of the presence of central nervous system metastases, according to Misako Nagasaka, MD, PhD.
Latest:
Best Treatment Selection in Clear-Cell RCCMedical experts describe the decision-making process between choosing an IO-IO vs an IO-TKI regimen for first-line treatment, considering factors such as safety profile and response in both community and academic settings.
Latest:
Experts Discuss Personalized ctDNA Assays to Predict Immunotherapy ResponseCancerNetwork® recaps a Between the Lines journal club program with George Ansstas, MD, and Firas B. Badin, MD.
